Compensated Awareness Post View
Disclaimer
Stellar Biotechnologies (SBOTF), Biovest International Ink KLH Supply Agreement
Biotech companies Stellar Biotechnologies and Biovest International have signed a definitive supply agreement to establish the terms for the production and supply of Stellar KLH™ to Biovest for use as an active component in BiovaxID® active immunotherapy for the treatment of follicular non-Hodgkin’s lymphoma.
KLH (Keyhole Limpet Hemocyanin) is an immune-stimulating protein commonly used as a carrier molecule in active immunotherapy drugs in development for certain cancers and other diseases. The supply agreement will meet Biovest’s requirements for Stellar’s KLH products for use in its BiovaxID® immunotherapy vaccine in commercial distribution as well as for future clinical trials.
“Stellar’s key growth initiative is to leverage our Stellar KLH™ technology into multiple clinical pathways and the BiovaxID® program is a good example of the value of our core business for this purpose,” Frank Oakes, president and chief executive officer of Stellar Biotechnologies, stated in the news release. “There are many new KLH-based immunotherapies advancing in clinical trials and we are positioning Stellar to be the leading company capable of delivering the scalable, sustainable supplies of KLH that will be needed by these pharmaceutical pipelines.”
Per the agreement, Stellar will deliver its KLH products to Biovest in accordance with the cGMP standards that are required for Biovest’s ongoing development and as an anticipated commercial supply. Biovest has agreed to purchase Stellar KLH™ at forecasted quantities and prices. In addition to the supply agreement’s initial three-year term, Biovest may renew the agreement for additional one-year periods.
The supply agreement provides for Stellar and Biovest to consummate a separate quality agreement, within three months, to list the quality aspects and procedures relating to manufacture and release of the cGMP-compliant Stellar KLH™. Biovest will appoint Stellar as the exclusive supplier of KLH in connection with the potential future commercialization of BiovaxID®, subject to negotiation and execution of commercial production and supply terms.
“We are pleased to collaborate with Stellar Biotechnologies to continue the clinical progress of our active immunotherapy (BiovaxID) and are proud to work with Stellar in anticipation of our future commercial success. BiovaxID immunotherapy has demonstrated ability in long-running clinical trials to elicit potent anti-tumor immune responses and extend remission duration in patients suffering from follicular non-Hodgkin’s lymphoma. If approved, we anticipate that this product will offer an innovative adjuvant/consolidation vaccine strategy for patients with this disease,” said Carlos Santos, Biovest Chief Executive Officer Carlos Santos.
For more information visit: www.stellarbiotech.com
